Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Breakout Labs has backed over 30 companies since it handed out the first batch of grants in 2012.
X-Chem will screen its DNA-encoded libraries to discover novel antivirals for Gilead.
Insmed aims to bring a first-in-market therapy to patients in the U.S. suffering from NTM lung disease caused by MAC, a chronic and debilitating condition.
Enyo Pharma has successfully identified potential targets of its preclinical molecule series EYP002 with Charles River's technology.
HitGen has formed a drug discovery research collaboration with Boehringer Ingelheim to identify novel small-molecule leads.
Bay Area drug discovery company Verge Genomics has formed industry and academic alliances in neuro disorders.
Aquila BioMedical signed an extended contract with Macrophage Pharma to support its preclinical immuno-oncology programs.
Science Exchange is providing its R&D service marketplace to QB3, the University of California incubator for life sciences startups.
Janssen has developed a mobile toolkit for trial supply management and patient engagement that can track adherence to each pill.
Biopharma executives share how they manage outsourcing relationships at this year's Drug Development Forum.
Treos Bio has tapped PPD to manage its first-in-human study on its lead cancer vaccine for colorectal cancer.